SALT LAKE CITY, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, “Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort,” won the best poster honor at the 27th Annual EAU Congress in Paris, France over the weekend. The poster was also presented at 2012 Genitourinary Cancers Symposium in San Francisco, California on February 2, 2012. The study concluded that the Prolaris Score demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence.
